Last reviewed · How we verify
NCT07266675
Post-Acute Phase of Cardiogenic Shock
trial in Cardiogenic Shock in 350 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Mackay Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 19 July 2024 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2028 |
| Sites | 1 location across Taiwan |
Conditions studied
- Cardiogenic Shock — all drugs for Cardiogenic Shock →
Sponsor
Mackay Memorial Hospital
Who can join
18 and older, any sex, with Cardiogenic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Epidemiology studies showed that the burden of cardiogenic shock (CS) persistently high, with increasing annual medical expenses and steady prevalence. In-hospital and one-year mortality reduce annually. Hence, there are increasing number of patients who survive to hospital discharge but they will face further challenges in the subacute stage after hospital discharge. However, there are still insufficient studies focusing on this issue. Establishment of a healthcare neatwork to help hospital survivors of CS return society safely is critical.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07266675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiogenic Shock
Currently open trials in the same condition.
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07345559 — Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock · NA · recruiting
- NCT07374289 — On Scene ECPR in Ostrava · NA · recruiting
- NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
- NCT07309029 — Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR · recruiting
Other Mackay Memorial Hospital trials
Trials by the same sponsor.
- NCT07370285 — AI-Supported Empathy Mapping to Enhance Communication and Grit in Pediatric Nursing Students · NA · not yet recruiting
- NCT07537816 — Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients · Phase 4 · not yet recruiting
- NCT07479654 — AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease · NA · not yet recruiting
- NCT05483634 — Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause · not yet recruiting
- NCT07118267 — The Intervention of Lactobacillus Plantarum Probiotics in Adult Autistic Spectrum Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07266675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mackay Memorial Hospital
- Last refreshed: 5 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07266675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing